

QMP

JUN 23 1994

RANDY B. WEISS, D.O.
FOUR STATES IMAGING
P.O. BOX 2785
JOPLIN, MO 64803
ATTN: WEISS, RANDY B., D.O.

Docket Number: 3032826
License Number: 24-26424-01

Dear Dr. Weiss:

This refers to the review of your written Quality Management Program (QMP) submitted in accordance with 10 CFR 35.32. A review of the QMP was performed to determine whether policies and procedures have been developed to meet the objectives of the rule. Based on this submission, there appear to be significant weaknesses and potential substantial failure of your QMP to meet the objectives in 10 CFR 35.32 in that:

Regarding I-125 and /or I-131 > 30 Microcuries

A footnote to 10 CFR 35.32(a)(1) provides that an oral revision to a written directive is acceptable if, because of the patient's condition, a delay in order to provide a written revision to an existing written directive would jeopardize the patient's health. Oral revisions must be documented immediately in the patient's record and a revised written directive must be signed and dated by an authorized user or physician under the supervision of an authorized user within 48 hours of the oral revision. Please include such a policy in your QMP.

If, because of the emergent nature of the patient's condition, a delay in order to provide a written directive would jeopardize the patient's health, an oral directive will be acceptable provided that the information provided in the oral directive is documented immediately in the patient's record and a written directive is prepared within 24 hours of the oral directive. Please include such a policy in your QMP.

Revisions to written directives may be made for any diagnostic or therapeutic procedure provided that the revision is dated and signed by an authorized user prior to the administration of the

9502060236 920615
PDR ADOCK 03032826
C PDR

JUN 23 1994

radiopharmaceutical dosage. Your QMP must include a policy/procedure that requires that revisions to written directives will be made prior to administration.

Your submittal for I-125 and/or I-131 > 30 microcuries administration does not include policies/procedures that ensure before administration that each administration is in accordance with the written directive as required by 10 CFR 35.32(a)(4). Describe your policy/procedure to verify, before administering the by-product material, that the specific details of the administration are in accordance with the written directive.

The dosage should be confirmed by the person administering the radiopharmaceutical to verify agreement with the written directive; that is, the dosage should be measured in the dose calibrator and the results compared with the prescribed dosage in the written directive. Please provide such (or similar) procedures in your QMP.

Your QMP should include a policy for instruction of all workers to seek guidance if they do not understand how to carry out the written directive. Please include such a provision in your QMP.

A commitment to retain each written directive and a record of each administered radiopharmaceutical dosage for three years after the date of administration is required in 10 CFR 35.32(d). Describe the procedure for an authorized user or a qualified individual under the supervision of an authorized user (e.g., a nuclear medicine physician, physicist or technologist), after administering a radiopharmaceutical, to make, date, sign or initial a written record that documents the administered dosage in an auditable form.

As required in 10 CFR 35.32(c), the licensee shall evaluate and respond, within 30 days after discovery of the recordable event, to each recordable event by: (a) assembling the relevant facts including the cause, (b) identifying what, if any, corrective action is required to prevent recurrence, and (c) retaining a record, in an auditable form, for three years, of the relevant facts and what corrective action was taken. Please include such a provision in your QMP.

JUN 23 1994

Your QMP should include a procedure to expand the number of cases reviewed when a misadministration or recordable event is uncovered during the periodic review of your QMP. Please include such a provision in your QMP.

Please provide assurance that modifications to your QMP will be submitted to the NRC within 30 days after the modification has been made as required by 10CFR 35.32(e).

Please provide assurance that records of each QMP review and evaluation will be maintained for three years as required in 10 CFR 35.32 (b)(3).

To meet the requirements in 10 CFR 35.32, you may choose to utilize the procedures described in Regulatory Guide 8.33(enclosed), or submit procedures that are equivalent. If you choose to use Regulatory Guide 8.33, be certain that the procedures you select are adjusted to meet the specific needs of your program as necessary. Additionally, you are reminded that training and/or instruction of supervised individuals in your QMP is required by 10 CFR 35.25.

Due to the apparent failure of your written QMP to meet the objectives in 10 CFR 35.32, you must immediately modify your written QMP to address the items listed above, and provide those modifications to your NRC regional office within 30 days of the date of this letter. NRC will review these matters during your next routine NRC inspection to determine whether violations of NRC requirements have occurred. Enforcement action may be taken at that time for failure to meet the requirements of 10 CFR 35.32.

Please be advised that this QMP will not be incorporated into your license by condition. This allows you the flexibility to make changes to your quality management program without obtaining prior NRC approval. When modifications are made to your program, You should submit any changes to your QMP to this Office within 30 days as required by 10 CFR 35.32(e).

Your QMP was reviewed by an NRC contractor following a standard review plan and related checklist provided by the NRC staff. This letter outlining the findings of that review was prepared by the contractor utilizing standard paragraphs previously reviewed and approved by NRC Headquarters and regional management.

JUN 23 1994

If you have any questions, please call Region III at (708) 829-9887.

Sincerely,

John R. Madera, Chief
Materials Licensing Section

Enclosure: As stated

bcc w/o enclosure:

M. Lanza
S. Merchant, NMSS

RIII

Madera